-
Something wrong with this record ?
Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma
M. Fedorko, M. Stanik, R. Iliev, M. Redova-Lojova, T. Machackova, M. Svoboda, D. Pacik, J. Dolezel, O. Slaby,
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT13547
MZ0
CEP Register
NV15-34678A
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Source
Source
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
26426010
DOI
10.3390/ijms161023382
Knihovny.cz E-resources
- MeSH
- Carcinoma, Renal Cell blood genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- MicroRNAs blood MeSH
- Biomarkers, Tumor blood MeSH
- Kidney Neoplasms blood genetics MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Case-Control Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p<0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p<0.0001). Increased level of miR-378 positively correlates with disease-free survival (p=0.036) and clinical stage (p=0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.
Central European Institute of Technology Masaryk University Brno 62500 Czech Republic
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno 65653 Czech Republic
Department of Urologic Oncology Masaryk Memorial Cancer Institute Brno 65653 Czech Republic
Department of Urology University Hospital Brno and Masaryk University Brno Brno 62500 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028160
- 003
- CZ-PrNML
- 005
- 20201116155346.0
- 007
- ta
- 008
- 161005s2015 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms161023382 $2 doi
- 024 7_
- $a 10.3390/ijms161023382 $2 doi
- 035 __
- $a (PubMed)26426010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Fedorko, Michal $u Department of Urology, University Hospital Brno and Masaryk University Brno, Brno 62500, Czech Republic. michal.fedorko@fnbrno.cz. $7 xx0121526
- 245 10
- $a Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma / $c M. Fedorko, M. Stanik, R. Iliev, M. Redova-Lojova, T. Machackova, M. Svoboda, D. Pacik, J. Dolezel, O. Slaby,
- 520 9_
- $a Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p<0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p<0.0001). Increased level of miR-378 positively correlates with disease-free survival (p=0.036) and clinical stage (p=0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 650 _2
- $a karcinom z renálních buněk $x krev $x genetika $7 D002292
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x krev $x genetika $7 D007680
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x krev $7 D035683
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Staník, Michal, $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. stanik@mou.cz. $d 1977- $7 xx0141428
- 700 1_
- $a Iliev, Robert $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. 269069@mail.muni.cz. Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic. 269069@mail.muni.cz. $7 _AN063401
- 700 1_
- $a Lojová, Martina, $u Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic. martina.redova@gmail.com. $d 1983- $7 mub2011663118
- 700 1_
- $a Machackova, Tana $u Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic. tana.machackova@gmail.com.
- 700 1_
- $a Svoboda, Marek, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. msvoboda@mou.cz. $d 1975- $7 xx0098478
- 700 1_
- $a Pacík, Dalibor, $u Department of Urology, University Hospital Brno and Masaryk University Brno, Brno 62500, Czech Republic. dalibor.pacik@gmail.com. $d 1955- $7 nlk19990073648
- 700 1_
- $a Doležel, Jan, $u Department of Urologic Oncology, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. dolezel@mou.cz. $d 1956- $7 xx0064982
- 700 1_
- $a Slabý, Ondřej, $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic. slaby@mou.cz. Central European Institute of Technology, Masaryk University, Brno 62500, Czech Republic. slaby@mou.cz. $d 1981- $7 js20030220015
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 16, č. 10 (2015), s. 23382-23389
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26426010 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20201116155344 $b ABA008
- 999 __
- $a ok $b bmc $g 1166474 $s 952790
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 16 $c 10 $d 23382-23389 $e 20150929 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a NT13547 $p MZ0
- GRA __
- $a NV15-34678A $p MZ0
- LZP __
- $a Pubmed-20161005